Telomir Pharmaceuticals Publishes Preclinical Data Showing Improved Insulin Sensitivity in Type 2 Diabetes Model

Telomir Pharmaceuticals (NASDAQ: TELO) has announced the peer-reviewed publication of preclinical data in Biomedicine & Pharmacotherapy showing that its lead candidate, Telomir-Zn, restored insulin sensitivity and improved glucose homeostasis in a diet-induced zebrafish model of Type 2 diabetes. The study reported dose-dependent reductions in fasting blood glucose and insulin levels, improved glucose tolerance, and significantly lowered HOMA-IR scores, a widely used measure of insulin resistance.

The findings add to a growing body of evidence supporting Telomir-Zn’s mechanism of action through modulation of intracellular metal homeostasis. The company noted that the biological pathways targeted by Telomir-Zn have been implicated in both metabolic disease and cancer, and said the results complement the company’s recently FDA-cleared Phase 1/2 clinical program evaluating the drug in patients with advanced or metastatic triple-negative breast cancer.

Telomir Pharmaceuticals is a preclinical-stage biotechnology company developing small-molecule therapeutics designed to target fundamental epigenetic and metabolic mechanisms implicated in cancer, aging, and degenerative disease. The company’s lead program, Telomir-1 (Telomir-Zn), has demonstrated activity in preclinical studies involving modulation of intracellular metal homeostasis, redox balance, epigenetically regulated gene expression, mitochondrial function, and genomic stability.

For more information, visit the company’s newsroom at https://ibn.fm/TELO and the full press release at https://ibn.fm/BoK2F.

The implications of this announcement are significant for the field of metabolic disease, as insulin resistance is a key driver of Type 2 diabetes and related conditions. By demonstrating that Telomir-Zn can restore insulin sensitivity in a preclinical model, Telomir Pharmaceuticals has provided evidence that its approach targeting metal homeostasis may offer a novel therapeutic strategy. Furthermore, the overlap with pathways implicated in cancer suggests potential broader applications, which is reinforced by the ongoing clinical program in triple-negative breast cancer. These results could pave the way for new treatment options for patients with metabolic disorders who do not adequately respond to existing therapies.